Search

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

Heart Failure

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

A Planned Safety Net for Patients in Need

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Evolving the Unwearable Collection

Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

FDA approves treatment option for T2D in children 10 and older

FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers